Loading…
Amantadine has potential for the treatment of COVID-19 because it inhibits known and novel ion channels encoded by SARS-CoV-2
The dire need for COVID-19 treatments has inspired strategies of repurposing approved drugs. Amantadine has been suggested as a candidate, and cellular as well as clinical studies have indicated beneficial effects of this drug. We demonstrate that amantadine and hexamethylene-amiloride (HMA), but no...
Saved in:
Published in: | Communications biology 2021-12, Vol.4 (1), p.1347-10 |
---|---|
Main Authors: | , , , , , , , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | |
---|---|
cites | |
container_end_page | 10 |
container_issue | 1 |
container_start_page | 1347 |
container_title | Communications biology |
container_volume | 4 |
creator | Toft-Bertelsen, Trine Lisberg Jeppesen, Mads Gravers Tzortzini, Eva Xue, Kai Giller, Karin Becker, Stefan Mujezinovic, Amer Bentzen, Bo Hjorth B Andreas, Loren Kolocouris, Antonios Kledal, Thomas Nitschke Rosenkilde, Mette Marie |
description | The dire need for COVID-19 treatments has inspired strategies of repurposing approved drugs. Amantadine has been suggested as a candidate, and cellular as well as clinical studies have indicated beneficial effects of this drug. We demonstrate that amantadine and hexamethylene-amiloride (HMA), but not rimantadine, block the ion channel activity of Protein E from SARS-CoV-2, a conserved viroporin among coronaviruses. These findings agree with their binding to Protein E as evaluated by solution NMR and molecular dynamics simulations. Moreover, we identify two novel viroporins of SARS-CoV-2; ORF7b and ORF10, by showing ion channel activity in a X. laevis oocyte expression system. Notably, amantadine also blocks the ion channel activity of ORF10, thereby providing two ion channel targets in SARS-CoV-2 for amantadine treatment in COVID-19 patients. A screen of known viroporin inhibitors on Protein E, ORF7b, ORF10 and Protein 3a from SARS-CoV-2 revealed inhibition of Protein E and ORF7b by emodin and xanthene, the latter also blocking Protein 3a. This illustrates a general potential of well-known ion channel blockers against SARS-CoV-2 and specifically a dual molecular basis for the promising effects of amantadine in COVID-19 treatment. We therefore propose amantadine as a novel, cheap, readily available and effective way to treat COVID-19. |
doi_str_mv | 10.1038/s42003-021-02866-9 |
format | article |
fullrecord | <record><control><sourceid>proquest_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_f7013bc495364bc4bcb0878e0dba41ad</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_f7013bc495364bc4bcb0878e0dba41ad</doaj_id><sourcerecordid>2605601932</sourcerecordid><originalsourceid>FETCH-LOGICAL-d277t-b12cec06bdfb4b8e35f49bc9c5dc2c9718f6e52e9c517e00df463bbb356c63d23</originalsourceid><addsrcrecordid>eNpNkEtvFDEQhC0EIlHIH-AQ9ZGLE7_GMz6uNkBWihSJQK4jP3pYJzP2MvaCcuC_M3mKQ6ta1a2vpCLkI2ennMnurCjBmKRM8GU6ral5Qw6FNIZKrcTb__YDclzKLWOMG2O0VO_JgVRdI5f7Ifm7mmyqNsSEsLUFdrliqtGOMOQZ6hahzmjrtJiQB1hf3WzOKTfg0Nt9QYgVYtpGF2uBu5T_JLApQMq_cYSYE_itTQnHAph8DhjA3cP16ts1XecbKj6Qd4MdCx4_6xH58eXz9_UFvbz6ulmvLmkQbVup48KjZ9qFwSnXoWwGZZw3vgleeNPybtDYCFwM3iJjYVBaOudko72WQcgjsnnihmxv-90cJzvf99nG_tHI88_ezjX6EfuhZVw6r0yzdLeo8451bYcsOKu4DQvr0xNrN-dfeyy1n2LxOI42Yd6XXmjW6KVr-RB78vy6dxOG1-CX-uU_YOqINw</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2605601932</pqid></control><display><type>article</type><title>Amantadine has potential for the treatment of COVID-19 because it inhibits known and novel ion channels encoded by SARS-CoV-2</title><source>Publicly Available Content Database</source><source>PubMed Central</source><source>Springer Nature - nature.com Journals - Fully Open Access</source><creator>Toft-Bertelsen, Trine Lisberg ; Jeppesen, Mads Gravers ; Tzortzini, Eva ; Xue, Kai ; Giller, Karin ; Becker, Stefan ; Mujezinovic, Amer ; Bentzen, Bo Hjorth ; B Andreas, Loren ; Kolocouris, Antonios ; Kledal, Thomas Nitschke ; Rosenkilde, Mette Marie</creator><creatorcontrib>Toft-Bertelsen, Trine Lisberg ; Jeppesen, Mads Gravers ; Tzortzini, Eva ; Xue, Kai ; Giller, Karin ; Becker, Stefan ; Mujezinovic, Amer ; Bentzen, Bo Hjorth ; B Andreas, Loren ; Kolocouris, Antonios ; Kledal, Thomas Nitschke ; Rosenkilde, Mette Marie</creatorcontrib><description>The dire need for COVID-19 treatments has inspired strategies of repurposing approved drugs. Amantadine has been suggested as a candidate, and cellular as well as clinical studies have indicated beneficial effects of this drug. We demonstrate that amantadine and hexamethylene-amiloride (HMA), but not rimantadine, block the ion channel activity of Protein E from SARS-CoV-2, a conserved viroporin among coronaviruses. These findings agree with their binding to Protein E as evaluated by solution NMR and molecular dynamics simulations. Moreover, we identify two novel viroporins of SARS-CoV-2; ORF7b and ORF10, by showing ion channel activity in a X. laevis oocyte expression system. Notably, amantadine also blocks the ion channel activity of ORF10, thereby providing two ion channel targets in SARS-CoV-2 for amantadine treatment in COVID-19 patients. A screen of known viroporin inhibitors on Protein E, ORF7b, ORF10 and Protein 3a from SARS-CoV-2 revealed inhibition of Protein E and ORF7b by emodin and xanthene, the latter also blocking Protein 3a. This illustrates a general potential of well-known ion channel blockers against SARS-CoV-2 and specifically a dual molecular basis for the promising effects of amantadine in COVID-19 treatment. We therefore propose amantadine as a novel, cheap, readily available and effective way to treat COVID-19.</description><identifier>ISSN: 2399-3642</identifier><identifier>EISSN: 2399-3642</identifier><identifier>DOI: 10.1038/s42003-021-02866-9</identifier><identifier>PMID: 34853399</identifier><language>eng</language><publisher>England: Nature Portfolio</publisher><subject>Amantadine - pharmacology ; Amiloride - analogs & derivatives ; Amiloride - pharmacology ; Antiviral Agents - pharmacology ; Ion Channels - physiology ; Rimantadine - pharmacology ; SARS-CoV-2 - drug effects ; Viral Proteins - physiology</subject><ispartof>Communications biology, 2021-12, Vol.4 (1), p.1347-10</ispartof><rights>2021. The Author(s).</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><orcidid>0000-0002-6320-4452 ; 0000-0003-3216-9065 ; 0000-0001-7511-5898 ; 0000-0001-9600-3254 ; 0000-0003-2041-5740</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27923,27924,37012</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/34853399$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Toft-Bertelsen, Trine Lisberg</creatorcontrib><creatorcontrib>Jeppesen, Mads Gravers</creatorcontrib><creatorcontrib>Tzortzini, Eva</creatorcontrib><creatorcontrib>Xue, Kai</creatorcontrib><creatorcontrib>Giller, Karin</creatorcontrib><creatorcontrib>Becker, Stefan</creatorcontrib><creatorcontrib>Mujezinovic, Amer</creatorcontrib><creatorcontrib>Bentzen, Bo Hjorth</creatorcontrib><creatorcontrib>B Andreas, Loren</creatorcontrib><creatorcontrib>Kolocouris, Antonios</creatorcontrib><creatorcontrib>Kledal, Thomas Nitschke</creatorcontrib><creatorcontrib>Rosenkilde, Mette Marie</creatorcontrib><title>Amantadine has potential for the treatment of COVID-19 because it inhibits known and novel ion channels encoded by SARS-CoV-2</title><title>Communications biology</title><addtitle>Commun Biol</addtitle><description>The dire need for COVID-19 treatments has inspired strategies of repurposing approved drugs. Amantadine has been suggested as a candidate, and cellular as well as clinical studies have indicated beneficial effects of this drug. We demonstrate that amantadine and hexamethylene-amiloride (HMA), but not rimantadine, block the ion channel activity of Protein E from SARS-CoV-2, a conserved viroporin among coronaviruses. These findings agree with their binding to Protein E as evaluated by solution NMR and molecular dynamics simulations. Moreover, we identify two novel viroporins of SARS-CoV-2; ORF7b and ORF10, by showing ion channel activity in a X. laevis oocyte expression system. Notably, amantadine also blocks the ion channel activity of ORF10, thereby providing two ion channel targets in SARS-CoV-2 for amantadine treatment in COVID-19 patients. A screen of known viroporin inhibitors on Protein E, ORF7b, ORF10 and Protein 3a from SARS-CoV-2 revealed inhibition of Protein E and ORF7b by emodin and xanthene, the latter also blocking Protein 3a. This illustrates a general potential of well-known ion channel blockers against SARS-CoV-2 and specifically a dual molecular basis for the promising effects of amantadine in COVID-19 treatment. We therefore propose amantadine as a novel, cheap, readily available and effective way to treat COVID-19.</description><subject>Amantadine - pharmacology</subject><subject>Amiloride - analogs & derivatives</subject><subject>Amiloride - pharmacology</subject><subject>Antiviral Agents - pharmacology</subject><subject>Ion Channels - physiology</subject><subject>Rimantadine - pharmacology</subject><subject>SARS-CoV-2 - drug effects</subject><subject>Viral Proteins - physiology</subject><issn>2399-3642</issn><issn>2399-3642</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>DOA</sourceid><recordid>eNpNkEtvFDEQhC0EIlHIH-AQ9ZGLE7_GMz6uNkBWihSJQK4jP3pYJzP2MvaCcuC_M3mKQ6ta1a2vpCLkI2ennMnurCjBmKRM8GU6ral5Qw6FNIZKrcTb__YDclzKLWOMG2O0VO_JgVRdI5f7Ifm7mmyqNsSEsLUFdrliqtGOMOQZ6hahzmjrtJiQB1hf3WzOKTfg0Nt9QYgVYtpGF2uBu5T_JLApQMq_cYSYE_itTQnHAph8DhjA3cP16ts1XecbKj6Qd4MdCx4_6xH58eXz9_UFvbz6ulmvLmkQbVup48KjZ9qFwSnXoWwGZZw3vgleeNPybtDYCFwM3iJjYVBaOudko72WQcgjsnnihmxv-90cJzvf99nG_tHI88_ezjX6EfuhZVw6r0yzdLeo8451bYcsOKu4DQvr0xNrN-dfeyy1n2LxOI42Yd6XXmjW6KVr-RB78vy6dxOG1-CX-uU_YOqINw</recordid><startdate>20211201</startdate><enddate>20211201</enddate><creator>Toft-Bertelsen, Trine Lisberg</creator><creator>Jeppesen, Mads Gravers</creator><creator>Tzortzini, Eva</creator><creator>Xue, Kai</creator><creator>Giller, Karin</creator><creator>Becker, Stefan</creator><creator>Mujezinovic, Amer</creator><creator>Bentzen, Bo Hjorth</creator><creator>B Andreas, Loren</creator><creator>Kolocouris, Antonios</creator><creator>Kledal, Thomas Nitschke</creator><creator>Rosenkilde, Mette Marie</creator><general>Nature Portfolio</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7X8</scope><scope>DOA</scope><orcidid>https://orcid.org/0000-0002-6320-4452</orcidid><orcidid>https://orcid.org/0000-0003-3216-9065</orcidid><orcidid>https://orcid.org/0000-0001-7511-5898</orcidid><orcidid>https://orcid.org/0000-0001-9600-3254</orcidid><orcidid>https://orcid.org/0000-0003-2041-5740</orcidid></search><sort><creationdate>20211201</creationdate><title>Amantadine has potential for the treatment of COVID-19 because it inhibits known and novel ion channels encoded by SARS-CoV-2</title><author>Toft-Bertelsen, Trine Lisberg ; Jeppesen, Mads Gravers ; Tzortzini, Eva ; Xue, Kai ; Giller, Karin ; Becker, Stefan ; Mujezinovic, Amer ; Bentzen, Bo Hjorth ; B Andreas, Loren ; Kolocouris, Antonios ; Kledal, Thomas Nitschke ; Rosenkilde, Mette Marie</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-d277t-b12cec06bdfb4b8e35f49bc9c5dc2c9718f6e52e9c517e00df463bbb356c63d23</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Amantadine - pharmacology</topic><topic>Amiloride - analogs & derivatives</topic><topic>Amiloride - pharmacology</topic><topic>Antiviral Agents - pharmacology</topic><topic>Ion Channels - physiology</topic><topic>Rimantadine - pharmacology</topic><topic>SARS-CoV-2 - drug effects</topic><topic>Viral Proteins - physiology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Toft-Bertelsen, Trine Lisberg</creatorcontrib><creatorcontrib>Jeppesen, Mads Gravers</creatorcontrib><creatorcontrib>Tzortzini, Eva</creatorcontrib><creatorcontrib>Xue, Kai</creatorcontrib><creatorcontrib>Giller, Karin</creatorcontrib><creatorcontrib>Becker, Stefan</creatorcontrib><creatorcontrib>Mujezinovic, Amer</creatorcontrib><creatorcontrib>Bentzen, Bo Hjorth</creatorcontrib><creatorcontrib>B Andreas, Loren</creatorcontrib><creatorcontrib>Kolocouris, Antonios</creatorcontrib><creatorcontrib>Kledal, Thomas Nitschke</creatorcontrib><creatorcontrib>Rosenkilde, Mette Marie</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>MEDLINE - Academic</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>Communications biology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Toft-Bertelsen, Trine Lisberg</au><au>Jeppesen, Mads Gravers</au><au>Tzortzini, Eva</au><au>Xue, Kai</au><au>Giller, Karin</au><au>Becker, Stefan</au><au>Mujezinovic, Amer</au><au>Bentzen, Bo Hjorth</au><au>B Andreas, Loren</au><au>Kolocouris, Antonios</au><au>Kledal, Thomas Nitschke</au><au>Rosenkilde, Mette Marie</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Amantadine has potential for the treatment of COVID-19 because it inhibits known and novel ion channels encoded by SARS-CoV-2</atitle><jtitle>Communications biology</jtitle><addtitle>Commun Biol</addtitle><date>2021-12-01</date><risdate>2021</risdate><volume>4</volume><issue>1</issue><spage>1347</spage><epage>10</epage><pages>1347-10</pages><issn>2399-3642</issn><eissn>2399-3642</eissn><abstract>The dire need for COVID-19 treatments has inspired strategies of repurposing approved drugs. Amantadine has been suggested as a candidate, and cellular as well as clinical studies have indicated beneficial effects of this drug. We demonstrate that amantadine and hexamethylene-amiloride (HMA), but not rimantadine, block the ion channel activity of Protein E from SARS-CoV-2, a conserved viroporin among coronaviruses. These findings agree with their binding to Protein E as evaluated by solution NMR and molecular dynamics simulations. Moreover, we identify two novel viroporins of SARS-CoV-2; ORF7b and ORF10, by showing ion channel activity in a X. laevis oocyte expression system. Notably, amantadine also blocks the ion channel activity of ORF10, thereby providing two ion channel targets in SARS-CoV-2 for amantadine treatment in COVID-19 patients. A screen of known viroporin inhibitors on Protein E, ORF7b, ORF10 and Protein 3a from SARS-CoV-2 revealed inhibition of Protein E and ORF7b by emodin and xanthene, the latter also blocking Protein 3a. This illustrates a general potential of well-known ion channel blockers against SARS-CoV-2 and specifically a dual molecular basis for the promising effects of amantadine in COVID-19 treatment. We therefore propose amantadine as a novel, cheap, readily available and effective way to treat COVID-19.</abstract><cop>England</cop><pub>Nature Portfolio</pub><pmid>34853399</pmid><doi>10.1038/s42003-021-02866-9</doi><tpages>10</tpages><orcidid>https://orcid.org/0000-0002-6320-4452</orcidid><orcidid>https://orcid.org/0000-0003-3216-9065</orcidid><orcidid>https://orcid.org/0000-0001-7511-5898</orcidid><orcidid>https://orcid.org/0000-0001-9600-3254</orcidid><orcidid>https://orcid.org/0000-0003-2041-5740</orcidid><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 2399-3642 |
ispartof | Communications biology, 2021-12, Vol.4 (1), p.1347-10 |
issn | 2399-3642 2399-3642 |
language | eng |
recordid | cdi_doaj_primary_oai_doaj_org_article_f7013bc495364bc4bcb0878e0dba41ad |
source | Publicly Available Content Database; PubMed Central; Springer Nature - nature.com Journals - Fully Open Access |
subjects | Amantadine - pharmacology Amiloride - analogs & derivatives Amiloride - pharmacology Antiviral Agents - pharmacology Ion Channels - physiology Rimantadine - pharmacology SARS-CoV-2 - drug effects Viral Proteins - physiology |
title | Amantadine has potential for the treatment of COVID-19 because it inhibits known and novel ion channels encoded by SARS-CoV-2 |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-08T06%3A50%3A33IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Amantadine%20has%20potential%20for%20the%20treatment%20of%20COVID-19%20because%20it%20inhibits%20known%20and%20novel%20ion%20channels%20encoded%20by%20SARS-CoV-2&rft.jtitle=Communications%20biology&rft.au=Toft-Bertelsen,%20Trine%20Lisberg&rft.date=2021-12-01&rft.volume=4&rft.issue=1&rft.spage=1347&rft.epage=10&rft.pages=1347-10&rft.issn=2399-3642&rft.eissn=2399-3642&rft_id=info:doi/10.1038/s42003-021-02866-9&rft_dat=%3Cproquest_doaj_%3E2605601932%3C/proquest_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-d277t-b12cec06bdfb4b8e35f49bc9c5dc2c9718f6e52e9c517e00df463bbb356c63d23%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2605601932&rft_id=info:pmid/34853399&rfr_iscdi=true |